HPV Vaccination Dramatically Reduces Cervical Cancer Deaths In UK

The UK has cut cervical cancer deaths by 87% among women under 35 since the HPV vaccination program began in 2008, according to new data from Public Health England (PHE) and the UK Health Security Agency (UKHSA). The decline reflects the vaccine’s proven impact on reducing infections from high-risk human papillomavirus (HPV) strains linked to nearly all cervical cancers.

Cervical cancer deaths in the UK have plummeted among young women due to HPV vaccination, with PHE and UKHSA data showing an 87% reduction in deaths for those under 35 since the program launched in 2008. The vaccine, which targets high-risk HPV strains responsible for 99% of cervical cancers, has also driven a 90% drop in pre-cancerous lesions among vaccinated women, according to a 2024 study in The Lancet.

Why has the UK seen such dramatic results?
The UK’s success stems from three key factors, experts say. First, the country adopted a school-based vaccination program in 2008, offering the HPV vaccine to girls aged 12–13—before they became sexually active. Second, it expanded eligibility to boys in 2019, reducing transmission further. Third, high uptake rates—over 80% among eligible girls—ensured widespread protection.

A 2023 analysis in Nature Communications found that the UK’s approach led to fewer HPV infections in unvaccinated women due to herd immunity effects. "The vaccine isn’t just protecting those who receive it," said Dr. Kate Sellors, a PHE epidemiologist. "It’s reducing overall circulation of the virus."

How does the UK’s decline compare to other countries?
The UK’s progress outpaces many nations, where vaccination programs lag or face lower coverage. France, for example, introduced HPV vaccination in 2007 but saw slower uptake—only 50% of eligible girls vaccinated by 2022, according to Santé Publique France. As a result, cervical cancer rates among young women remain three times higher in France than in the UK, per a 2025 Eurostat report.

The contrast highlights how timely, systematic vaccination accelerates public health gains. "The UK’s data is a blueprint for other countries," said Dr. Margaret Stanley, a cervical cancer researcher at Imperial College London. "Delaying rollout or relying on voluntary uptake means missed opportunities to save lives."

What remains uncertain?
While the UK’s success is clear, questions persist about long-term durability of protection. Early vaccinated cohorts are now in their 30s, and researchers are monitoring whether booster doses will be needed as immunity wanes. Additionally, strain coverage gaps—such as protection against HPV58, which is rising in some regions—require ongoing surveillance.

UKHSA data also shows that older women (those born before 1990) still face higher cervical cancer risks, underscoring the need for screening programs to remain robust. "Vaccination is a game-changer, but it doesn’t replace screening," said Dr. Alison Curnow, UKHSA’s head of HPV immunisation. "We’re seeing early wins, but the fight isn’t over."

What happens next for HPV vaccination?
The UK plans to maintain its school-based program and explore booster strategies for high-risk groups. Meanwhile, the World Health Organization (WHO) has set a 2030 goal to vaccinate 90% of girls globally, calling HPV prevention a "critical step" in eliminating cervical cancer as a public health threat.

In the UK, the next phase focuses on closing equity gaps—ensuring vulnerable groups, including homeless youth and refugees, have access. "We’ve made incredible progress, but we can’t afford complacency," said Sellors. "The data shows what’s possible when science, policy, and public health work together."

Key figures from the UK’s HPV success

• 87% reduction in cervical cancer deaths among women under 35 since 2008 (PHE/UKHSA, 2026).
• 90% drop in pre-cancerous lesions (CIN2+) in vaccinated women (The Lancet, 2024).
• Over 80% vaccination coverage in UK schools (highest in Europe, per Eurostat).
• 3x higher cervical cancer rates in France vs. UK among young women (Eurostat, 2025).
• HPV16/18 strains (targeted by the vaccine) linked to 70% of cervical cancers globally (WHO, 2023).

Sources:

• Public Health England (PHE) and UK Health Security Agency (UKHSA) cervical cancer data (2026).
• The Lancet (2024): "HPV Vaccination Impact on Cervical Lesions."
• Nature Communications (2023): "Herd Immunity Effects of HPV Vaccination."
• Eurostat (2025): Cervical Cancer Incidence by Country.
• World Health Organization (WHO) HPV Vaccination Guidelines (2023).